Novartis AG has in-licensed a new compound for the treatment of hepatitis C that is described as the first in a new class of drugs called cyclophilin inhibitors. The deal was announced on 9 February, 2010 but no financial details were disclosed. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
